AnteoTech (ADO) investor relations material

Business Focus and Product Positioning

• Specializes in in vitro diagnostics and immunoassays, leveraging proprietary surface chemistry and AnteoBind NXT for new product development due to high switching costs.

• AnteoBind NXT offers improved performance, lower costs, and workflow benefits, enabling more sensitive, reproducible, and cost-effective immunodiagnostic tests.

• Focuses on bioconjugation, supporting a range of applications with up to 45x assay signal improvement, one-step activation, and reduced material usage by up to 90%.

• Emphasizes involvement in new markets, especially India, and collaborates with major institutions like Serum Institute of India, Thermo Fisher Scientific, and Merck.

• Holds a broad IP portfolio with patent families in life sciences and advanced battery technologies.

Market Strategy and Growth Initiatives

• Early-stage assessment of global chemiluminescence (CLIA) and ELISA markets, aiming to move up the value chain by making AnteoBind NXT a core ingredient in end products.

• Exploring ELISA plates, biosensors, and other diagnostic applications as growth areas, with technical papers and collaborations underway.

• Strategic partnerships and collaborations are key, focusing on complementing core competencies and expanding global reach.

• Pipeline and sample evaluations have grown across Europe, North America, India, and Asia, with streamlined sales and marketing processes.

• Targets adjacent opportunities in superconductors, water treatment, coatings, air filtration, textiles, and niche agrochemicals.

Sales, Operations, and Shareholder Engagement

• Significant focus on increasing sales since June of the previous year, with a larger and more progressive sales pipeline.

• Investments in CRM and sales team development are yielding results, with new channels being used to reach customers.

• Maintains a large, long-term retail shareholder base, reflecting strong support from the retail market.

• Transparency and measured communication are prioritized, with public updates tied to material contract milestones.

• Engages with research partners and distributors globally to expand reach and adoption.